Sam Fazeli

Which bucket would you put that in?

I know it's not a bio, but is it a beta or a same or how would you classify that drug?

In terms of potential outside of China, of course, the complication potentially is that iBrands is heading for genericization.

And you've also got two pretty hefty competitors in the forms of Qiskali and iBrands.

Palbociclib.

So we have palbociclib, ribociclib, etc.

So anyway, we're in a world that's complicated.

But I often find that drugs that do have better CNS penetration do have an opportunity to really take hold when you've got a disease where CNS metastasis is a significant part of it.

So let's hope that that's the case.

Now, in another area that's also breast cancer, potentially not focused, but also impacts breast cancer is the HLX2022, which is a HER2 targeting antibody with non-overlapping epitopes with other drugs, particularly trastuzumab.

So I'm just interested in your thinking about where that fits in the, what is the target product profile here?

How do you feel that would fit with the

Evolving competition from drugs like Xanidatamab, Alphamab, KNO26, of course, N-HER2, which is an ADC, and Remagen, which is also an ADC, Dicitamab, Vedotin.

What's your thinking there?

Thank you for that.

So there is, I think maybe, is it an obvious question?

Is this something that you could use as a backbone for an ADC also?

And then if not, could you see it as a combo with a, this is about vedotin or a nher2?

And you don't see a risk of interference between the two antibodies because they have different epitopes?

Yeah.